Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review

Katrine B Hansen1, Tina Vilsbøll2, Filip K Knop21Department of Clinical Physiology, Glostrup Hospital, University of Copenhagen, Denmark; 2Diabetes Research Division, Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, DenmarkAbstract: Type 2 diabetes melli...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Katrine B Hansen, Tina Vilsbøll, Filip K Knop
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2010
Materias:
Acceso en línea:https://doaj.org/article/8c64de7374424824b9bf9975cd63ed86
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:8c64de7374424824b9bf9975cd63ed86
record_format dspace
spelling oai:doaj.org-article:8c64de7374424824b9bf9975cd63ed862021-12-02T05:33:56ZIncretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review1178-7007https://doaj.org/article/8c64de7374424824b9bf9975cd63ed862010-05-01T00:00:00Zhttp://www.dovepress.com/incretin-mimetics-a-novel-therapeutic-option-for-patients-with-type-2--a4450https://doaj.org/toc/1178-7007Katrine B Hansen1, Tina Vilsbøll2, Filip K Knop21Department of Clinical Physiology, Glostrup Hospital, University of Copenhagen, Denmark; 2Diabetes Research Division, Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, DenmarkAbstract: Type 2 diabetes mellitus is a metabolic disease associated with low quality of life and early death. The goal in diabetes treatment is to prevent these outcomes by tight glycemic control and minimizing vascular risk factors. So far, even intensified combination regimen with the traditional antidiabetes agents have failed to obtain these goals. Incretin mimetics are a new class of antidiabetes drugs which involve modulation of the incretin system. They bind to and activate glucagon-like peptide-1 (GLP-1) receptors on pancreatic beta-cells following which insulin secretion and synthesis are initiated. Since the compounds have no insulinotropic activity at lower glucose concentrations the risk of hypoglycemia – a well-known shortcoming of existing antidiabetes treatments – is low. Additionally, incretin mimetics have been shown to be associated with beneficial effects on cardiovascular risk factors such as weight loss, decrease in blood pressure and changes in lipid profile. Current clinical data on the two available incretin mimetics, exenatide and liraglutide, are evaluated in this review, focusing on pharmacology, efficacy, safety and tolerability. The review is built on a systematic PubMed and Medline search for publications with the key words GLP-1 receptor agonist, exenatide, liraglutide and type 2 diabetes mellitus up to January 2009.Keywords: glucagon-like peptide-1 (GLP-1), exenatide, liraglutide, type 2 diabetes Katrine B HansenTina VilsbøllFilip K KnopDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2010, Iss default, Pp 155-163 (2010)
institution DOAJ
collection DOAJ
language EN
topic Specialties of internal medicine
RC581-951
spellingShingle Specialties of internal medicine
RC581-951
Katrine B Hansen
Tina Vilsbøll
Filip K Knop
Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review
description Katrine B Hansen1, Tina Vilsbøll2, Filip K Knop21Department of Clinical Physiology, Glostrup Hospital, University of Copenhagen, Denmark; 2Diabetes Research Division, Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, DenmarkAbstract: Type 2 diabetes mellitus is a metabolic disease associated with low quality of life and early death. The goal in diabetes treatment is to prevent these outcomes by tight glycemic control and minimizing vascular risk factors. So far, even intensified combination regimen with the traditional antidiabetes agents have failed to obtain these goals. Incretin mimetics are a new class of antidiabetes drugs which involve modulation of the incretin system. They bind to and activate glucagon-like peptide-1 (GLP-1) receptors on pancreatic beta-cells following which insulin secretion and synthesis are initiated. Since the compounds have no insulinotropic activity at lower glucose concentrations the risk of hypoglycemia – a well-known shortcoming of existing antidiabetes treatments – is low. Additionally, incretin mimetics have been shown to be associated with beneficial effects on cardiovascular risk factors such as weight loss, decrease in blood pressure and changes in lipid profile. Current clinical data on the two available incretin mimetics, exenatide and liraglutide, are evaluated in this review, focusing on pharmacology, efficacy, safety and tolerability. The review is built on a systematic PubMed and Medline search for publications with the key words GLP-1 receptor agonist, exenatide, liraglutide and type 2 diabetes mellitus up to January 2009.Keywords: glucagon-like peptide-1 (GLP-1), exenatide, liraglutide, type 2 diabetes
format article
author Katrine B Hansen
Tina Vilsbøll
Filip K Knop
author_facet Katrine B Hansen
Tina Vilsbøll
Filip K Knop
author_sort Katrine B Hansen
title Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review
title_short Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review
title_full Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review
title_fullStr Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review
title_full_unstemmed Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review
title_sort incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review
publisher Dove Medical Press
publishDate 2010
url https://doaj.org/article/8c64de7374424824b9bf9975cd63ed86
work_keys_str_mv AT katrinebhansen incretinmimeticsanoveltherapeuticoptionforpatientswithtype2diabetesampndashareview
AT tinavilsbamposlashll incretinmimeticsanoveltherapeuticoptionforpatientswithtype2diabetesampndashareview
AT filipkknop incretinmimeticsanoveltherapeuticoptionforpatientswithtype2diabetesampndashareview
_version_ 1718400362598105088